Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) - guidance (TA576)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
17 April 2019

Abstract

NICE is unable to make a recommendation about the use in the NHS of bosutinib (Bosulif) for untreated chronic myeloid leukaemia in adults because no evidence submission was received from Pfizer. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance